Does efalizumab modulate T cell function both in vivo and in vitro?
These observations suggest that efalizumab treatment induces a state of T cell hyporesponsiveness and provide an explanation as to why efalizumab is effective in patients with stable psoriasis, but often fails to control disease flares. When maintained over a prolonged period of time the observed T cell hyporeactivity may conceivably put efalizumab recipients at an increased risk of biologically relevant immunosuppression.
A lack of bony support for the implant represents an unfavorable situation from biomechanical point of view that should be considered and solved. As clinical problems mostly occur at the marginal bone region (bacterial plaque accumulation, overcontoured abutments, infections, osseous defects), attention should be focused on this region.